PURPOSE: To determine the impact of postoperative radiation therapy (POXRT) on outcome in spinal cord gliomas. PATIENTS AND METHODS: Data from 242 patients were collected retrospectively from six institutions using a standardized data sheet. Pathology specimens, when available, were centrally reviewed. RESULTS: A total of 183 patients were analyzed: 82 received surgery alone as initial treatment, whereas 101 had surgery and POXRT. Demographic, diagnostic, and treatment factors were analyzed for impact on progression-free (PFS) and overall survival (OS). PFS in ependymoma patients was 74%, 60%, and 35% at 5, 10, 15 years, respectively, and was significantly influenced by treatment type, race, age, tumor grade, and type of surgery on univariate analysis, with age being the only significant factor on multivariate analysis (MVA) (p = 0.01). OS of ependymoma patients was 91%, 84%, and 75% at 5, 10, and 15 years, respectively, and was significantly influenced by both complete resection (p = 0.04) and age (p = 0.03) on MVA. In astrocytomas, PFS was 42%, 29%, and 15% at 5, 10, and 15 years, and was significantly influenced by POXRT in low- and intermediate-grade tumors on MVA (p = 0.02). OS at 5, 10, and 15 years was 59%, 53%, and 32%, respectively, and was significantly influenced by grade on MVA (p < 0.01). CONCLUSION: Postoperative radiation therapy reduced disease progression in low- and moderate-grade astrocytomas. In ependymomas, complete resection significantly influenced OS.
PURPOSE: To determine the impact of postoperative radiation therapy (POXRT) on outcome in spinal cord gliomas. PATIENTS AND METHODS: Data from 242 patients were collected retrospectively from six institutions using a standardized data sheet. Pathology specimens, when available, were centrally reviewed. RESULTS: A total of 183 patients were analyzed: 82 received surgery alone as initial treatment, whereas 101 had surgery and POXRT. Demographic, diagnostic, and treatment factors were analyzed for impact on progression-free (PFS) and overall survival (OS). PFS in ependymomapatients was 74%, 60%, and 35% at 5, 10, 15 years, respectively, and was significantly influenced by treatment type, race, age, tumor grade, and type of surgery on univariate analysis, with age being the only significant factor on multivariate analysis (MVA) (p = 0.01). OS of ependymomapatients was 91%, 84%, and 75% at 5, 10, and 15 years, respectively, and was significantly influenced by both complete resection (p = 0.04) and age (p = 0.03) on MVA. In astrocytomas, PFS was 42%, 29%, and 15% at 5, 10, and 15 years, and was significantly influenced by POXRT in low- and intermediate-grade tumors on MVA (p = 0.02). OS at 5, 10, and 15 years was 59%, 53%, and 32%, respectively, and was significantly influenced by grade on MVA (p < 0.01). CONCLUSION: Postoperative radiation therapy reduced disease progression in low- and moderate-grade astrocytomas. In ependymomas, complete resection significantly influenced OS.
Authors: Rahul D Tendulkar; Atmaram S Pai Panandiker; Shengjie Wu; Larry E Kun; Alberto Broniscer; Robert A Sanford; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-24 Impact factor: 7.038
Authors: Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300
Authors: Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 12.300
Authors: Mohamad H Fakhreddine; Anita Mahajan; Marta Penas-Prado; Jeffrey Weinberg; Ian E McCutcheon; Vinay Puduvalli; Paul D Brown Journal: Neuro Oncol Date: 2013-01-14 Impact factor: 12.300
Authors: Bernard L Maria; Nalin Gupta; Anne G Gilg; May Abdel-Wahab; Anthony P Leonard; Mark Slomiany; William G Wheeler; Lauren B Tolliver; Michael A Babcock; John T Lucas; Bryan P Toole Journal: J Child Neurol Date: 2008-10 Impact factor: 1.987
Authors: Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa Journal: Neuro Oncol Date: 2012-12-09 Impact factor: 12.300